Fragmented QRS complexes are associated with left ventricular systolic and diastolic dysfunctions in patients with metabolic syndrome by Oner, Ender et al.
Address for correspondence: Ender Oner, MD, Kardiyoloji Kliniği, Mehmet Akif Ersoy Göğüs Kalp ve Damar Cerrahisi, 
Eğitim ve Araştırma Hastanesi, İstasyon Mah, Turgut Özal Bulvarı No:11 Küçükçekmece, 34303, Istanbul, Turkey,  
tel: +90 212 692 20 00, fax: +90 212 471 94 94, e-mail: enderoner7@gmail.com
Received: 31.05.2015 Accepted: 06.07.2015
Fragmented QRS complexes are associated with 
left ventricular systolic and diastolic dysfunctions 
in patients with metabolic syndrome
Ender Oner1, Mehmet Erturk1, Ali Birant1, Ali Kemal Kalkan1, Fatih Uzun1,  
Yalcin Avci2, Muhammet Gurdogan3, Hamdi Pusuroglu1, Aydin Yildirim1
1Department of Cardiology, Stanbul Mehmet Akif Ersoy Thoracic and Cardiovascular  
Surgery Training and Research Hospital, Istanbul, Turkey 
2Clinic of Cardiology, Istanbul Bahcelievler State Hospital, Turkey 
3Clinic of Cardiology, Edirne State Hospital, Turkey
Abstract
Background: Metabolic syndrome (MetS) is found to be associated with deterioration of the 
left ventricular (LV) systolic and diastolic functions. One of the factors for this impairment 
is myocardial fibrosis. Fragmented QRS (fQRS) complexes are found to be associated with 
myocardial fibrosis. The aim of the study was to evaluate if the presence of fQRS on electrocar-
diogram (ECG) can detect pronounced impairment in the LV systolic and diastolic functions 
in MetS patients.
Methods: The study included 111 (mean age 47 ± 9, 49.5% male) MetS patients and  
96 (mean age 45 ± 9, 58.3% male) control subjects without MetS. ECG was evaluated for the 
presence of fQRS. Each patient underwent conventional echocardiography and tissue Doppler 
imaging.
Results: Fragmented QRS was more common among MetS patients (26.1% vs. 14.6%, p = 0.041).  
MetS was associated with subclinical LV systolic and LV diastolic dysfunctions. In subgroup 
analyses of MetS patients, the presence of fQRS on ECG had a higher E/E’ ratio and lower 
E’ velocity, indicating pronounced diastolic dysfunction, as well as lower isovolumic accelera-
tion (IVA), indicating profound subclinical LV systolic dysfunction. E/E’ ratio and IVA were 
independent predictors of fQRS presence in patients with MetS.
Conclusions: Fragmented QRS is more common among MetS patients compared to non- 
-MetS patients. The presence of fQRS is associated with pronounced subclinical LV systolic 
and diastolic dysfunctions in MetS patients. (Cardiol J 2015; 22, 6: 691–698)
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Introduction
Metabolic syndrome (MetS) consists of a clus-
tering of several metabolic and physiological risk 
factors, including hyperglycemia, hypertriglyceri-
demia, lower high-density lipoprotein cholesterol 
(HDL-C), hypertension, and abdominal obesity [1]. 
MetS is diagnosed when three or more of these 
metabolic abnormalities are present in the same 
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Education Program Adult Treatment Panel III 
(NCEP ATP III) [2]. MetS has been shown to be 
associated with left ventricular (LV) systolic and 
diastolic dysfunctions [3–5]. The mechanism be-
hind cardiac impairment in MetS is multifactorial, 
but one of the pivotal contributors is thought to be 
myocardial fibrosis [6, 7].
Fragmented QRS (fQRS) includes various 
RSR’ patterns with different morphologies of the 
QRS complexes with or without the Q wave on 
a resting 12-lead electrocardiogram (ECG). Various 
RSR’ patterns include an additional R wave (R’) or 
notching in the nadir of the S wave, or the pres-
ence of > 1 R’ (fragmentation) in 2 contiguous 
leads, corresponding to a major coronary artery 
territory [8]. Fragmented QRS has been shown to 
be a marker of myocardial fibrosis or scar tissue, 
and has been found to be associated with increased 
adverse cardiac events [9, 10]. The aim of this study 
was to determine if fQRS is more common in MetS 
patients and if the presence of fQRS on ECG can 
detect pronounced impairment in LV systolic and 
diastolic functions in MetS patients.
Methods
This study was an observational case-control 
study.
Study population
The study was performed at the Mehmet 
Akif Ersoy Thoracic and Cardiovascular Surgery 
Training and Research Hospital in Istanbul, Turkey. 
Participants enrolled in the study were selected 
among patients admitted to the cardiology outpa-
tient clinic from January 2012 to November 2013. 
The study population included 111 (mean age 
47 ± 9, 49.5% male) consecutive patients with MetS 
and 96 (mean age 45 ± 9, 58.3% male) control 
subjects without MetS.
The exclusion criteria of the present study 
were defined as follows: angina, acute coronary 
syndrome, heart failure history, congenital, peri-
cardial and valvular heart disease, atrial fibrillation 
or flutter, secondary hypertension, renal disease, 
thyroid disorders, malignancies, chronic obstruc-
tive pulmonary disease, pulmonary hypertension, 
atrioventricular conduction abnormality, any QRS 
morphology with a QRS duration 120 ms or more 
(bundle branch block patterns; left, right bundle 
branch block and intraventricular conduction 
delay), segmental wall motion abnormalities, LV 
ejection fraction (LVEF) < 55%, pregnancy, and 
inflammatory diseases. Written informed consent 
was obtained from all patients following approval 
of the study by the Institutional Review Board. 
The study was consistent with the Declaration of 
Helsinki.
Study protocol
Patients with MetS and control subjects with-
out MetS were included in the study. The following 
demographic data were collected for all patients: 
age, sex, smoking status, body mass index (BMI), 
waist circumference, heart rate, and blood pres-
sure. Blood samples were drawn following an 
overnight fasting period to measure fasting serum 
glucose, plasma lipids (i.e., triglyceride, HDL-C, 
total cholesterol, and low-density lipoprotein cho-
lesterol [LDL-C] concentrations) and creatinine. 
Standard 12-lead ECGs were taken. Conventional 
echocardiography and tissue Doppler imaging were 
performed on all the subjects.
Diagnosis and definitions
The diagnosis of MetS was based on the 
presence of 3 or more of the risk factors for MetS 
established by the NCEP ATP III 2005 guidelines: 
systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) ≥ 130/≥ 85 mm Hg, fasting plasma 
glucose ≥ 100 mg/dL, waist circumference > 102 cm 
for men and > 88 cm for women, fasting triglyc-
erides > 150 mg/dL, and HDL-C < 40 mg/dL for 
men and < 50 mg/dL for women [2]. Diagnosis of 
diabetes was based on the criteria of the World 
Health Organization published in 2006 [11], and 
arterial hypertension was based on the recom-
mendations of the European Society of Cardiology 
Hypertension Guideline, published in 2007 [12].
Electrocardiogram
Standard 12-lead surface resting ECGs (filter 
range, 0.5–150 Hz, 25 mm/s, 10 mm/mV) were 
recorded for all the patients. These ECGs were 
evaluated by 2 cardiologists blinded to the pa-
tient data. Fragmented QRS was defined by the 
presence of various RSR’ patterns (QRS duration 
< 120 ms) with or without Q wave, which includes 
an additional R wave (R’) or notching of the 
R wave or S wave, or the presence of more than one 
R’ fragmentation without typical bundle branch 
block in 2 contiguous leads corresponding to a major 
coronary artery territory [8]. The standard 12-lead 
ECG was analyzed without using any magnification.
Conventional echocardiographic examination
All transthoracic echocardiographic exami-
nations were performed with the GE Vivid S6 
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Vingmed System 5 (Norway, Horten), which is 
equipped with 2.5–4 MHz transducers. All pa-
tients were examined in the left lateral and supine 
positions with 2 dimensional, M-mode, pulsed, 
and tissue Doppler echocardiography. Single-lead 
ECG recordings were obtained continuously. For 
all measurements, the average of at least 5 cardiac 
cycles was used.
M-mode measurements and conventional 
Doppler echocardiographic examinations were per-
formed based on the criteria of the American Soci-
ety of Echocardiography and European Society of 
Echocardiography guidelines [13]. LV end-systolic 
and end-diastolic dimensions were measured in the 
parasternal long-axis views. LVEF was estimated 
by Simpson’s rule. Left atrial maximum volume 
was measured in apical 4-chamber view at end-di-
astole. The mitral inflow peak velocity during early 
filling (E) and late filling from atrial contraction (A) 
were measured. The LV mass was calculated using 
the formula as previously described [14]. LV mass 
index (LVMI) was indexed for the surface area.
Tissue Doppler imaging
Doppler tissue echocardiography was per-
formed using transducer frequencies between 
3.5 and 4.0 MHz by adjusting the spectral-pulsed 
Doppler signal filters until a Nyquist limit of 
15 to 20 cm/s was reached, and then using the mini - 
mal optimal gain. Five consecutive cycles were re-
corded using a frame rate greater than 150 fps. The 
monitor sweep speed was set at 50 to 100 mm/s 
to optimize the spectral display of myocardial 
velocities. Every effort was made to align the 
pulsed-wave cursor to ensure that the Doppler 
angle of incidence was as close to 0 as possible to 
the direction of the walls. In the apical 4-chamber 
view, the pulsed Doppler sample volume was 
placed at the level of the LV mitral annulus end 
expiration [15].
The peak myocardial velocity during isovo-
lumic contraction (IVV), acceleration time (AT) 
of peak myocardial velocity during isovolumic 
contraction, peak myocardial systolic velocity (Sa), 
peak early and late diastolic velocities (E’ and A’), 
isovolumic contraction time (IVCT), isovolumic 
relaxation time (IVRT), and ejection time (ET) 
were measured. The E/E’ ratio was calculated. The 
myocardial performance index (MPI) was calcu-
lated as the sum of the IVCT and the IVRT divided 
by the ET. The isovolumic acceleration (IVA) was 
defined as the ratio of IVV divided by the AT. All 
measurements were obtained by a single observer 
who was blinded to the clinical details.
Statistical analyses
Statistical analyses were performed using the 
SPSS software version 17.0 for Windows (SPSS 
Inc., Chicago, Illinois, USA). The variables were 
investigated using visual (histograms, probabil-
ity plots) and analytical methods (Kolmogorov-
Smirnov/Shapiro-Wilk’s test) to determine the 
normal distribution. Descriptive analyses are 
presented using means and standard deviation. The 
categorical variables are expressed as numbers and 
percentages. Numerical variables were compared 
using a Student’s t-test or the Mann-Whitney 
U test. Categorical data were compared with the 
c2 test. Spearman correlation coefficients were 
used to assess the relationship between continuous 
variables. Stepwise logistic univariate and mul-
tivariate regression analyses were conducted to 
identify significant determinants of fQRS. A p value 
of less than 0.05 was considered significant.
Results
Analyses of the study population
Demographic, clinical, and laboratory parameters 
of patients and control groups are shown in Table 1. 
There were no significant differences between two 
groups in terms of age, gender, smoking status, heart 
rate, serum creatinine, and total cholesterol levels. 
MetS patients had significantly higher SBP, DBP, 
waist circumference, triglycerides, BMI, LDL-C, and 
fasting plasma glucose level than the controls. HDL-C 
levels were lower in the MetS group than in the 
control group. Fragmented QRS was more common 
among MetS patients (26.1% vs. 14.6%, p = 0.041).
LV end-systolic and diastolic diameters and 
LVEF were similar between the two groups. LVMI, 
interventricular septum (IVS), posterior wall (PW), 
and left atrial (LA) max volume were higher in 
patients with MetS. In terms of diastolic function, 
conventional Doppler parameters E and A, tissue 
Doppler parameters E’ and A’, and E/E’ ratio were 
significantly impaired in MetS patients. Although 
Sa and IVV were similar between the two groups, 
IVA was significantly reduced in patients with 
MetS. The MPI reflecting both systolic and dias-
tolic functions was significantly higher in patients 
with MetS compared to the controls (Table 2).
Subgroup analyses of MetS patients
After finding that fQRS is more common 
among MetS patients, they were divided into two 
groups: the fQRS (+) group (29 patients) and 
fQRS (–) group (81 patients). Then we compared 
all the parameters between these groups. In fQRS 
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(+) MetS patients, LV end-systolic and diastolic 
diameters, LVEF, A, Sa, and IVV parameters were 
similar compared to fQRS (–) patients. In fQRS (+) 
MetS patients, LVMI, IVS, PW and LA max volume, 
E, E/E’, A’, and MPI were higher, while E’ and IVA 
were lower (Table 3).
The results of the correlation analyses are 
shown in Table 4. Fragmented QRS was positively 
Table 1. Demographic, clinic and laboratory parameters of patients with or without metabolic  
syndrome (MetS).
MetS– (n = 96) MetS+ (n = 111) P 
Age [years] 45 ± 9 47 ± 9 0.090
Sex, male 56 (58.3%) 55 (49.5%) 0.206
Smoking 28 (29.2%) 32 (28.8%) 0.957
Body mass index [kg/m2] 27 ± 4 30 ± 4 < 0.001
Waist circumference [cm] 92 ± 10 103 ± 10 < 0.001
Diastolic blood pressure [mm Hg] 85 ± 13 94 ± 11 < 0.001
Systolic blood pressure [mm Hg] 138 ± 21 151 ± 2 < 0.001
Heart rate [bpm] 77 ± 12 77 ± 13 0.896
Fasting plasma glucose [mg/dL] 94 ± 8 109 ± 9 < 0.001
HDL-C [mg/dL] 54 ± 17 42 ± 10 < 0.001
Triglyceride [mg/dL] 114 ± 67 208 ± 115 < 0.001
Total cholesterol [mg/dL] 205 ± 42 214 ± 41 0.100
LDL-C [mg/dL] 129 ± 39 140 ± 31 0.033
Creatinine [mg/dL] 0.79 ± 0.15 0.79 ± 0.16 0.944
Fragmented fQRS 14 (14.6%) 29 (26.1%) 0.041
HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol
Table 2. Conventional and tissue Doppler imaging measurements of left ventricle.
MetS– (n = 96) MetS+ (n = 111) P 
LVEDD [mm] 48.2 ± 4.2 48.1 ± 4.2 0.850
LVESD [mm] 29.6±4.0 29.2 ± 3.2 0.462
Interventricular septum (mm) 10.5 ± 2.0 11.6 ± 1.9 < 0.001
Posterior wall [mm] 9.1 ± 1.5 9.9 ± 1.5 < 0.001
Ejection fraction [%] 67.5 ± 5.2 66.4 ± 4.9 0.142
LV mass index [g/m2] 90.4 ± 23.0 101.1 ± 23.8 0.001
LA maximum volume [mL] 47.8 ± 13.8 53.2 ± 11.5 0.003
E velocity [cm/s] 83.7 ± 13.9 79.3 ± 14.3 0.025
A velocity [cm/s] 70.0 ± 16.1 78.2 ± 17.2 0.001
E’ velocity [cm/s] 11.8 ± 3.3 9.7 ± 2.4 < 0.001
A’ velocity [cm/s] 11.5 ± 2.2 12.5 ± 1.9 0.001
E/E’ ratio 7.6 ± 2.9 8.6 ± 2.8 0.018
Sa [cm/s] 9.4 ± 1.5 9.4 ± 1.7 0.764
IVV [cm/s] 7.3 ± 2.2 7.7 ± 2.1 0.167
IVA [m/s2] 2.9 ± 0.9 2.4 ± 0.4 < 0.001
MPI 0.47 ± 0.1 0.5 ± 0.1 0.001
MetS — metabolic syndrome; LV — left ventricular; LVEDD — left ventricular end diastolic diameter; LVESD — left ventricular end systolic diameter; 
E — mitral inflow peak early diastolic wave velocity; A — mitral inflow peak late diastolic wave velocity E’ — flow velocity of the early diastole 
using tissue Doppler echocardiography; A’ — flow velocity of the late diastole using tissue Doppler echocardiography; Sa — peak velocity of 
myocardial systolic wave; IVV — isovolumic velocity; IVA — isovolumic acceleration; MPI — myocardial performance index
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correlated with DBP and SBP, waist circumfer-
ence, triglyceride levels, IVS, PW, LV mass index, 
LA max volume, E velocity, A’ velocity, E/E’ ratio, 
and MPI. HDL levels, E’ velocity, and IVA were 
inversely correlated with fQRS. There was no 
correlation between fQRS and age, fasting plasma 
glucose levels, number of risk factors, A velocity, 
Sa, or BMI.
In univariate analysis, to predict the presence 
of fQRS in MetS patients, DBP and SBP, HDL 
and triglyceride levels, E/E’ ratio, LV mass index, 
LA max volume, and IVA were found to be pa-
rameters associated with fQRS (Table 5). After 
adjustment for potential confounders, fQRS was 
associated with E/E’ ratio and IVA in multivariate 
logistic regression analysis.
Discussion
This study demonstrated that: 1) fQRS is more 
common in MetS patients; 2) MetS is associated 
with subclinical LV systolic dysfunction and LV 
diastolic dysfunction; 3) in subgroup analyses of 
MetS patients, the presence of fQRS on ECG was 
associated with more prominent subclinical LV sys-
tolic and LV diastolic dysfunctions; 4) the presence 
of fQRS is correlated with MetS components and 
LV systolic and diastolic parameters; and 5) E/E’ 
ratio and IVA were independent predictors of fQRS 
presence in patients with MetS.
Metabolic syndrome is an escalating public-
health problem. The prevalence of MetS in in-
dustrialized countries is about 22% of the adult 
population and over 40% of those aged 50 and older 
[16]. MetS is associated with a 5-fold increase in 
the risk of type 2 diabetes mellitus and 2-fold risk 
of developing cardiovascular disease over the next 
5 to 10 years [17]. MetS is known to be associated 
with deterioration in LV systolic and diastolic 
functions [3–5]. Myocardial fibrosis is thought to 
be one of the contributors to this deterioration 
[6, 7, 18]. Myocardial fibrosis can be diagnosed 
histopathologically and with the help of cardiac 
magnetic resonance imaging and scintigraphic 
methods [19, 20]. These methods are not readily 
available and are rather expensive.
Fragmented QRS on ECG has been found 
a marker of myocardial scarring or fibrosis in 
various diseases [8, 21, 22]. It can serve as an 
inexpensive and readily available electrocardio-
graphic index of myocardial fibrosis. The preva-
lence of fQRS was found to be 9.2% among healthy 
Table 3. Echocardiographic parameters of metabolic syndrome patients with and without fragmented 
QRS (fQRS).
fQRS– (n = 81) fQRS+ (n = 29) P 
LVEDD [mm] 47.7 ± 3.7 49.2 ± 5.3 0.151
LVESD [mm] 28.6 ± 2.9 30.3 ± 3.8 0.077
Interventricular septum [mm] 11.2 ± 1.9 12.7 ± 1.5 < 0.001
Posterior wall [mm] 9.7 ± 1.5 10.6 ± 1.6 0.001
Ejection fraction [%] 66.3 ± 5.1 66.6 ± 4.1 0.873
LV mass index [g/m2] 93.7 ± 21.1 121.0 ± 18.6 < 0.001
LA maximum volume 51.4 ± 11.7 58.2 ± 9.4 0.005
E velocity [cm/s] 76.3 ± 12.7 87.6 ± 15.4 < 0.001
A velocity [cm/s] 78.7 ± 18.3 76.7 ± 13.0 0.589
E’ velocity [cm/s] 10.3 ± 2.5 8.0 ± 1.1 < 0.001
A’ velocity [cm/s] 12.2 ± 2.0 13.1 ± 1.4 0.023
E/E’ ratio 7.6 ± 2.4 11.5 ± 2.0 < 0.001
Sa [cm/s] 9.5 ± 1.8 9.0 ± 1.3 0.179
IVV [cm/s] 7.8 ± 2.1 7.7 ± 1.9 0.805
IVA [m/s2] 2.5 ± 0.45 2.0 ± 0.32 < 0.001
MPI 0.51 ± 0.08 0.59 ± 0.07 < 0.001
LV — left ventricular; LVEDD — left ventricular end diastolic diameter; LVESD — left ventricular end systolic diameter; IVS — interventricular 
septum; PW — posterior wall; LA max volume — left atrium maximum volume; E — mitral inflow peak early diastolic wave velocity; A —  
mitral inflow peak late diastolic wave velocity E’ — flow velocity of the early diastole using tissue Doppler echocardiography; A’ — flow velocity 
of the late diastole using tissue Doppler echocardiography; Sa — peak velocity of myocardial systolic wave; IVV — isovolumic velocity;  
IVA — isovolumic acceleration; MPI — myocardial performance index
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middle-aged Finnish subjects [23]. The prevalence 
is increased in various diseases, including ST el-
evation myocardial infarction (21.9%) [7], cardiac 
sarcoidosis (75%) [21], and chronic kidney disease 
(60%) [22]. These data suggest that fQRS preva-
lence increases with myocardial involvement. We 
found that the prevalence of fQRS is higher in MetS 
compared to non-MetS controls (26.1% vs. 14.6%, 
p = 0.041). Our control group was chosen from the 
cardiology outpatient clinic, and some patients had 
1 or 2 aspects of MetS. Our control group’s fQRS 
percentage can be expected to be higher than that 
of the healthy population.
Metabolic syndrome is known to be associated 
with deterioration in LV systolic and diastolic func-
tions [3–5]. Consistent with previous studies, in 
our study, MetS patients had diastolic dysfunction 
detected by lower E velocity and E’ velocity and 
higher A velocity, A’ velocity, E/E’ ratio than the 
non-MetS controls. LVEF and Sa were not differ-
ent, but tissue Doppler parameter IVA was lower 
in MetS patients, indicating LV subclinical systolic 
dysfunction. IVA reflects the acceleration of the 
myocardium at the very beginning of the isovolu-
mic contraction period. IVA remains unaffected by 
the changes in the preload and afterload within the 
physiological range [24]. It can detect even small 
changes in the contractile function and is well cor-
related with the invasive or noninvasive measures 
of LV dp/dt [24, 25]. This parameter has been suc-
cessfully validated in clinical studies [26, 27].
There is no data as to whether the presence of 
fQRS predicts pronounced LV systolic and diastolic 
dysfunction in MetS patients. In our study, the 
presence of fQRS on ECG in MetS patients was 
Table 5. Logistic regression analysis of fragmented QRS for both metabolic syndrome parameters and 
echocardiographic parameters in metabolic syndrome patients.
Unadjusted Adjusted
Odds ratio (95% CI) P Odds ratio (95% CI) P
Waist circumference 1.04 (0.99–1.09) 0.056 1.04 (0.95–1.13) 0.399
Diastolic blood pressure 1.04 (1.00–1.09) 0.038 0.97 (0.85–1.09) 0.970
HDL-C 0.94 (0.89–0.99) 0.033 0.94 (0.85–1.02) 0.936
Triglyceride 1.00 (1.00–1.01) 0.006 1.01 (0.99–1.02) 0.068
Systolic blood pressure 1.04 (1.01– .06) 0.001 1.07 (0.99–1.14) 0.058
Fasting plasma glucose 0.99 (0.98–1.01) 0.755
Risk factor number 1.09 (0.59–2.01) 0.772
E/E’ ratio 2.19 (1.58–3.03) < 0.001 1.53 (1.05–2.22) 0.024
LV mass index 1.06 (1.03–1.10) < 0.001 1.05 (1.00–1.11) 0.048
LA maximum volume 1.05 (1.01–1.09) 0.008 1.04 (0.95–1.13) 0.399
Isovolumic acceleration 0.04 (0.01–0.17) < 0.001 0.01 (0.01–0.26) 0.007
CI — confidence interval; HDL-C — high density lipoprotein cholesterol; E — mitral inflow peak early diastolic wave velocity; E’ — flow velocity 
of the early diastole using tissue Doppler echocardiography; LA — left atrium
Table 4. Correlation between presence of  
fragmented QRS with demographic and  





Waist circumference 0.208 0.029
Diastolic blood pressure 0.256 0.007
Systolic blood pressure 0.310 0.001
Fasting plasma glucose –0.069 0.475
Triglyceride 0.360 < 0.001
HDL-C –0.175 0.066
Number of risk factors 0.014 0.886
E velocity 0.325 0.001
A velocity –0.220 0.815
E’ velocity –0.429 < 0.001
A’ velocity 0.196 0.039
Sa –0.114 0.234
MPI 0.416 < 0.001
Isovolumic acceleration –0.493 < 0.001
LV mass index 0.523 < 0.001
Interventricular septum 0.365 < 0.001
Posterior wall 0.225 0.018
Body mass index 0.014 0.881
E/E’ ratio 0.687 < 0.001
LV maximum volume 0.273 0.004
HDL-C — high density lipoprotein cholesterol; E — mitral inflow 
peak early diastolic wave velocity; A — mitral inflow peak late  
diastolic wave velocity E’ — flow velocity of the early diastole using 
tissue Doppler echocardiography; A’ — flow velocity of the late  
diastole using tissue Doppler echocardiography; Sa — peak velocity 
of myocardial systolic wave; MPI — myocardial performance  
index; LV — left ventricle
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associated with pronounced diastolic dysfunction 
expressed by higher E/E’ ratio and lower E’ velocity. 
A novel tissue Doppler parameter IVA was lower 
in the fQRS-positive group, indicating subclinical 
LV systolic dysfunction. In light of these results, 
we think that the presence of fQRS on ECG is an 
indicator of pronounced LV systolic and diastolic 
dysfunction in MetS patients.
Metabolic syndrome consists of 5 metabolic 
and physiological risk factors. Particular com-
ponents of MetS — hypertension, diabetes, and 
obesity — have been found to be associated with 
myocardial fibrosis [28–30]. Kosmala et al. [7] used 
surrogate serological markers of fibrotic process-
es and myocardial deformation parameters, and 
showed that subclinical LV systolic dysfunction 
and diastolic dysfunction is associated with a high 
degree of fibrosis in MetS patients. In our study, 
the presence of fQRS was correlated with waist 
circumference, SBP and DBP, and triglyceride 
level. In univariate logistic regression analysis, 
the MetS parameters SBP and DBP, HDL, and 
triglyceride levels were associated with the pres-
ence of fQRS. In multivariate logistic regression 
analysis, only LV IVA and E/E’ ratio were inde-
pendent determinants of the presence of fQRS 
on ECG. In light of these data, we think that 
myocardial fibrosis occurs with the contribution 
of particular MetS components, and causes the 
deterioration of LV functions. Myocardial fibrosis 
causing pronounced dysfunction can be predicted 
by the presence of fQRS on ECG.
Limitations of the study
This study has several limitations. The first 
one is small sample size. Secondly, we did not as-
sess prospectively the effect of the presence of 
fQRS on mortality and morbidity. Thirdly, we did 
not show cardiac fibrosis histopathologically or 
with other imaging modalities. Finally, coronary 
artery disease was excluded based on history, 
electrocardiography, or echocardiography (wall mo-
tion abnormality), and we did not perform exercise 
stress tests or coronary angiography.
Conclusions
Fragmented QRS is more common in MetS 
patients than in non-MetS patients. The presence 
of fQRS is associated with pronounced subclinical 
LV systolic dysfunction and diastolic dysfunction 
in MetS patients.
Conflict of interest: None declared
References
1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet, 2005; 365: 1415–1418.
2. Grundy SM, Cleeman JI, Daniels SR et al. American Heart As-
sociation; National Heart, Lung and Blood Institute Scientific 
Statement. Circulation, 2005; 112: 2735–2732.
3. Erturk M, Oner E, Kalkan AK et al. Anatolian J Cardiol, 2015; 
15: 42–49.
4. Ivanovic B, Tadic M, Simic D. Are all criteria of metabolic syn-
drome equally harmful? Acta Cardiol, 2011; 66: 189–196.
5. Crendal E, Walther G, Vinet A et al. Myocardial deformation and twist 
mechanics in adults with metabolic syndrome: Impact of cumula- 
tive metabolic burden. Obesity (Silver Spring), 2013; 21: 679–686.
6. Sciarreta S, Ferrucci A, Ciavarella GM et al. Markers of inflam-
mation and fibrosis are related to cardiovascular damage in hy-
pertensive patients with metabolic syndrome. Am J Hypertens, 
2007; 20: 784–791.
7. Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, Mysiak A, 
Marwick TH Integrated backscatter as a fibrosis marker in the 
metabolic syndrome: Association with biochemical evidence of 
fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc 
Imag, 2012; 13: 459–467.
8. Das MK, Khan B, Jacob S, Kumar A, Mahentiran J. Significance 
of a fragmented QRS complex versus a Q wave in patients with 
coronary artery disease. Circulation, 2006; 113: 2495–2501.
9. Das MK, Michael MA, Suradi H et al. Usefulness of fragmented 
QRS on a 12-lead electrocardiogram in acute coronary syndrome 
for predicting mortality. Am J Cardiol, 2009; 104: 1631–1637.
10. Akgul O, Uyarel H, Pusuroglu O et al. Predictive value of 
a fragmented QRS complex in patients undergoing primary angio - 
plasty for ST elevation myocardial infarction. Ann Noninvasive 
Electrocardiol, 2015; 20: 263–272. doi: 10.1111/anec.12179. 
11. Who Guideline Development Committee. Definition and diagno-
sis of diabetes mellitus and intermediate hyperglycemia. Report 
of a WHO/IDF Consultation, Geneve 2006. 
12. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC 
Practice Guidelines for the Management of Arterial Hyperten-
sion: ESH-ESC Task Force on the Management of Arterial Hy-
pertension. J Hypertens, 2007; 25: 1751–1762. 
13. Lang RM, Biering M, Devereux RB et al. Recommendations for 
chamber quantification: A report from the American society of 
echocardiography’s guidelines and standards committee and the 
chamber quantification writing group, developed in conjunction 
with the European association of echocardiography, a branch of 
the European society of cardiology. J Am Soc Echocardiogr, 2005; 
18: 1440–1463. 
14. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic 
assessment of left ventricular hypertrophy: comparison to nec-
ropsy finding. Am J Cardiol, 1986; 57: 450–458. 
15. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. 
Recommendations for quantification of Doppler Echocardiogra-
phy: A report from the Doppler Quantification task force of the 
nomenclature and standards committee of the American Society 
of Echocardiography. J Am Soc Echocardiogr, 2002; 15: 167–184.
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syn-
drome among US adults: findings from the third National Health 
and Nutrition Examination Survey. JAMA, 2002; 287: 356–359.
17. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the meta-
bolic syndrome: a joint interim statement of the International 
Diabetes Federation Task Force on Epidemiology and Preven-
www.cardiologyjournal.org 697
Ender Oner et al., Importance of fragmented QRS in metabolic syndrome
tion; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atheroscle-
rosis Society; and International Association for the Study of 
Obesity. Circulation, 2009; 120: 1640–1645.
18. Kosmala W, Kosmala-Przewlocka M, Osadnik-Szczepanik H, My-
siak A, O’Moore-Sullivan T, Marwick TH. A randomized study 
of aldosterone antagonism on LV function, structure, and fibrosis 
markers in metabolic syndrome. J Am Coll Cardiol Imag, 2011; 
4: 1239–1249.
19. Anderson Kr, Sutton MG, Lie JT. Histopathological types of 
cardiac fibrosis in myocardial disease. J Pathol, 1979; 128: 79–85.
20. Ferrari VA, Witschey WR, Zhou R. Cardiac magnetic resonance 
assessment of myocardial fibrosis: honing new clinical tools. Circ 
Cardiovasc Imag, 2011; 4: 604–606.
21. Sculler JL, Olson MD, Zipse MM et al. Electrocardiographic chara-
cteristics in patients with pulmonary sarcoidosis indica ting cardiac 
involvement. J Cardiovasc Electrophysiol, 2011; 22: 1243–1248.
22. Adar A, Kiris A, Ulusoy S et al. Fragmented QRS in associa-
ted with subclinical left ventricular dysfunction in patients with 
chronic kidney disease. Acta Cardiol, 2014; 69: 385–390.
23. Terho HK, Tikkanen JT, Juntilla JM et al. Prevalence and prog-
nostic significance of fragmented QRS complex in middle-aged 
subjects with and without clinical or electrocardiographic evi-
dence of cardiac disease. Am J Cardiol, 2014; 114: 141–147. doi: 
10.1016/j.amjcard.2014.03.066. 
24. Vogel M, Schmidt MR, Kristiansen SB et al. Validation of myo-
cardial acceleration during isovolumic contraction as a novel 
noninvasive index of right ventricular contractility. Comparison 
with ventricular pressure–volume relations in an animal model. 
Circulation, 2002; 105: 1693–1699.
25. Hashimoto I, Li X-K, Bhat AH Jones M, Sahn DJ. Quantita-
tive assessment of regional peak myocardial acceleration during 
isovolumic contraction and relaxation times by tissue Doppler 
imaging. Heart, 2005; 91: 811–816.
26. Erturk M, Aksu HU, Celik O et al. Evaluation of the effect of mitral 
stenosis severity on the left ventricular systolic function using 
isovolumic myocardial acceleration. Cardiol J, 2014; 21: 442–448.
27. Erturk M, Buturak A, Pusuroglu H et al. Comparison of subclini-
cal left and right ventricular systolic dysfunction in non-dipper 
and dipper hypertensives: Impact of isovolumic acceleration. 
Clin Exp Hypertens, 2014; 36: 572–578.
28. Gonzales A, Lopez B, Diez J. Fibrosis in hypertensive heart 
disease role of the angiotensin-aldesteron system. Med Clin N 
Am, 2004; 88: 93–97.
29. Adeghate E, Singh J. Structural changes in myocardium during 
diabetes-induced cardiomyopathy. Heart Fail Rev, 2014; 19: 15–23.
30. Kosmala W, Kosmala-Przewlocka M, Osadnik-Szczepanik H, 
Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: 
A randomized controlled trial of aldosterone blockade. Heart, 
2013; 99: 320–326.
698 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 6
